Galderma PatientFi ASPIRE Signature Suite and Contract Pricing HCP Offer Terms & Conditions

This offer is limited to licensed U.S. healthcare providers who (i) are members of the ASPIRE Galderma Practice Rewards healthcare professional loyalty programs or are associated with a Galderma pricing contract (as determined by Galderma in its sole discretion) and (ii) qualify for the Galderma PRIVI single location offer, excluding healthcare providers in U.S. territories and possessions (“Qualifying HCPs”). This is a limited quantity offer subject to availability from Galderma. If you have questions about this offer, please call 1-844-5ASPIRE.

Offer 1

Beginning November 9, 2023 and ending December 31, 2024 (or earlier as determined by Galderma in its sole discretion), this offer provides a Qualifying HCP who makes a qualifying purchase of 20 syringes of Restylane®, Restylane-L®, Restylane® Silk, Restylane® Lyft, Restylane® Refyne, Restylane® Defyne, Restylane® Contour, Restylane® Kysse, and/or Restylane® Eyelight (“Restylane Filler”) and 8 kits (16 vials) of Sculptra® an opportunity to sign a Provider Agreement (and any associated agreements and documents) (the “Agreements”) provided by PatientFi, LLC (“PatientFi”) for access to Galderma PRIVI for twelve (12) months from the date of execution of the Agreements.

Purchases must be made in exact amounts of 20 syringes of Restylane Filler and 8 Sculptra kits to qualify. If a purchase qualifies the Qualifying HCP for both this offer and another ASPIRE promotional offer, the purchase shall be applied to the other ASPIRE promotional offer in lieu of this offer. Maximum of one (1) qualifying purchase per Qualifying HCP during the offer duration.

Offer 2

Beginning June 30, 2024 and ending December 31, 2024 (or earlier as determined by Galderma in its sole discretion), this offer provides a Qualifying HCP who makes a qualifying purchase of 42 syringes of Restylane®, Restylane-L®, Restylane® Silk, Restylane® Lyft, Restylane® Refyne, Restylane® Defyne, Restylane® Contour, Restylane® Kysse, and/or Restylane® Eyelight (“Restylane Filler”) an opportunity to sign a Provider Agreement (and any associated agreements and documents) (the “Agreements”) provided by PatientFi, LLC (“PatientFi”) for access to Galderma PRIVI for twelve (12) months from the date of execution of the Agreements.

Purchases must be made in exact amounts of 42 syringes of Restylane Filler to qualify. If a purchase qualifies the Qualifying HCP for both this offer and another ASPIRE promotional offer, the purchase shall be applied to the other ASPIRE promotional offer in lieu of this offer. Maximum of one (1) qualifying purchase per Qualifying HCP during the offer duration.

Additional Terms Applicable to Both Offers 1 and 2

In addition, if the Qualifying HCP enrolls 20 or more new patient Members per quarter in Galderma PRIVI (with quarters defined in relation to the HCP’s respective twelve (12) month Galderma PRIVI access and enrollment defined by PatientFi including, without limitation, patient Member execution of any Membership Agreement, authorization(s), and associated documents), the HCP shall also receive 12 $50 Provider Codes for use with their patients in ASPIRE. Maximum of 3 Provider Codes per patient: 1 for a qualifying Dysport® treatment, 1 per syringe for a qualifying Restylane® family treatment, and/or 1 per vial for a qualifying Sculptra® treatment. All Provider Codes shall expire sixty (60) days from the date issued.

Healthcare providers may use Provider Codes only for adult patients who receive treatment with a Galderma aesthetic product (“Galderma Product”) in accordance with the product’s FDA-approved indication and labeling. Member patients must also be members of the ASPIRE Galderma Rewards Consumer Loyalty Program (“ASPIRE”). Galderma employees or their spouses are not eligible to use Provider Codes.

Healthcare providers may be obligated to report information concerning this offer to third parties, including but not limited to Medicare, Medicaid, and other federal and state health care programs, if applicable. You are solely responsible for accurately reporting such information, including any discounts or rebates, as may be required by federal or state law.

All Provider Codes must be submitted by the treating healthcare provider via www.aspirepracticerewards.com. Galderma will reimburse the provider for the face value of used Provider Codes, provided that the provider has complied with these terms and conditions. Individual Provider Codes are valid for one-time use. Provider Codes cannot be combined with any other ASPIRE Benefits except ASPIRE Rewards and ASPIRE Gift Certificates (as such terms are defined in the ASPIRE terms and conditions). Provider Codes have no cash value without simultaneous purchase of a Galderma Product treatment. Provider Codes valid only in the U.S., excluding all its territories and possessions, and are void where prohibited, taxed or otherwise restricted by law.

Healthcare providers acknowledge that any discount or rebate provided hereunder is commensurate with the fair market value of the products. No discount or rebate provided hereunder is intended to be, nor shall it be construed as, an offer or payment made, whether directly or indirectly, to induce the referral of patients; the purchase, lease or order of any item or service from Galderma; or the recommending or arranging for the purchase, lease or order of any item or service from Galderma.

By participating in this offer, healthcare providers agree to all of the terms and conditions of this offer. Galderma assumes no responsibility for lost, late, incomplete, or incorrect submissions that fail to be properly entered and submitted to www.aspirepracticerewards.com for any reason. Provider Codes will be processed and reimbursed in U.S. dollars only. Galderma reserves the right to cancel or modify this offer without notice.

Beginning November 9, 2023 and ending December 31, 2024 (or earlier as determined by Galderma in its sole discretion), this offer provides a Qualifying HCP who makes a qualifying purchase of 40 syringes of Restylane®, Restylane-L®, Restylane® Silk, Restylane® Lyft, Restylane® Refyne, Restylane® Defyne, Restylane® Contour, Restylane® Kysse, and/or Restylane® Eyelight (“Restylane Filler”) and 16 kits (32 vials) of Sculptra® an opportunity to sign a Provider Agreement (and any associated agreements and documents) (the “Agreements”) provided by PatientFi, LLC (“PatientFi”) for access to Galderma PRIVI for twelve (12) months from the date of execution of the Agreements.

Purchases must be made in exact amounts of 40 syringes of Restylane Filler and 16 Sculptra kits to qualify. If a purchase qualifies a Qualifying HCP for both this offer and another ASPIRE promotional offer, the purchase shall be applied to the other ASPIRE promotional offer in lieu of this offer. Maximum of one (1) qualifying purchase per Qualifying HCP during the offer duration.

In addition, if the Qualifying HCP enrolls 40 or more new patient Members per quarter in Galderma PRIVI (with quarters defined in relation to the HCP’s respective twelve (12) month Galderma PRIVI access and enrollment defined by PatientFi including, without limitation, patient Member execution of any Membership Agreement, authorization(s), and associated documents), the HCP shall also receive 22 $50 Provider Codes for use with their patients in ASPIRE. Maximum of 3 Provider Codes per patient: 1 for a qualifying Dysport® treatment, 1 per syringe for a qualifying Restylane® family treatment, and/or 1 per vial for a qualifying Sculptra® treatment. All Provider Codes shall expire sixty (60) days from the date issued.

Additional Terms

Patients are eligible for this offer only if they pay for their entire Galderma treatments themselves and if no part of their treatments are covered by insurance or any other third party payor. This offer excludes any treatments using a Galderma Product that is reimbursed by Medicaid, Medicare, or any other federal or state benefit programs, including state medical assistance programs. Patients are not eligible for this offer if their private insurance, HMO, or any other health benefit program pays for all or part of their treatments. If any form of reimbursement is sought from a third-party, patients may be required to disclose the value of the Provider Codes to that party. Provider Codes are not available to patients who are Galderma employees or their spouses.

Galderma PatientFi ASPIRE Signature Suite and Contract Pricing HCP Offer Terms & Conditions

This offer is limited to licensed U.S. healthcare providers who (i) are members of the ASPIRE Galderma Practice Rewards Signature Suite healthcare professional loyalty program or (ii) qualify for the Galderma PRIVI multiple location offer and are associated with a Galderma pricing contract (both (i) and (ii) above are applicable only to healthcare providers who own or operate, or are employed by, a practice with 2 to 29 locations as determined by Galderma in its sole discretion and exclude healthcare providers in U.S. territories and possessions) (“Qualifying HCPs”). This is a limited quantity offer subject to availability from Galderma. If you have questions about this offer, please call 1-844-5ASPIRE.

Offer 1

Beginning November 9, 2023 and ending December 31, 2024 (or earlier as determined by Galderma in its sole discretion), this offer provides a Qualifying HCP’s practice that makes a qualifying purchase of 40 syringes of Restylane®, Restylane-L®, Restylane® Silk, Restylane® Lyft, Restylane® Refyne, Restylane® Defyne, Restylane® Contour, Restylane® Kysse, and/or Restylane® Eyelight (“Restylane Filler”) and 16 kits (32 vials) of Sculptra® an opportunity to sign a Provider Agreement (and any associated agreements and documents) (the “Agreements”) provided by PatientFi, LLC (“PatientFi”) for access to Galderma PRIVI for twelve (12) months from the date of execution of the Agreements.

Purchases must be made in exact amounts of 40 syringes of Restylane Filler and 16 Sculptra kits to qualify. If a purchase qualifies a Qualifying HCP’s practice for both this offer and another ASPIRE promotional offer, the purchase shall be applied to the other ASPIRE promotional offer in lieu of this offer. Maximum of one (1) qualifying purchase per Qualifying HCP’s practice during the offer duration.

Offer 2

Beginning June 30, 2024 and ending December 31, 2024 (or earlier as determined by Galderma in its sole discretion), this offer provides a Qualifying HCP’s practice that makes a qualifying purchase of 84 syringes of Restylane®, Restylane-L®, Restylane® Silk, Restylane® Lyft, Restylane® Refyne, Restylane® Defyne, Restylane® Contour, Restylane® Kysse, and/or Restylane® Eyelight (“Restylane Filler”) an opportunity to sign a Provider Agreement (and any associated agreements and documents) (the “Agreements”) provided by PatientFi, LLC (“PatientFi”) for access to Galderma PRIVI for twelve (12) months from the date of execution of the Agreements.

Purchases must be made in exact amounts of 84 syringes of Restylane Filler to qualify. If a purchase qualifies a Qualifying HCP’s practice for both this offer and another ASPIRE promotional offer, the purchase shall be applied to the other ASPIRE promotional offer in lieu of this offer. Maximum of one (1) qualifying purchase per Qualifying HCP’s practice during the offer duration.

Additional Terms Applicable to Both Offers 1 and 2

In addition, if the Qualifying HCP’s practice enrolls 40 or more new patient Members per quarter in Galderma PRIVI (with quarters defined in relation to the practice’s respective twelve (12) month Galderma PRIVI access and enrollment defined by PatientFi including, without limitation, patient Member execution of any Membership Agreement, authorization(s), and associated documents), the Qualifying HCP’s practice shall also receive 22 $50 Provider Codes for use with their patients in ASPIRE. Maximum of 3 Provider Codes per patient: 1 for a qualifying Dysport® treatment, 1 per syringe for a qualifying Restylane® family treatment, and/or 1 per vial for a qualifying Sculptra® treatment. All Provider Codes shall expire sixty (60) days from the date issued.

Healthcare providers may use Provider Codes only for adult patients who receive treatment with a Galderma aesthetic product (“Galderma Product”) in accordance with the product’s FDA-approved indication and labeling. Member patients must also be members of the ASPIRE Galderma Rewards Consumer Loyalty Program (“ASPIRE”). Galderma employees and their spouses are not eligible to use Provider Codes.

Healthcare providers may be obligated to report information concerning this Program to third parties, including but not limited to Medicare, Medicaid, and other federal and state health care programs, if applicable. You are solely responsible for accurately reporting such information, including any discounts or rebates, as may be required by federal or state law.

Galderma PatientFi ASPIRE Signature Suite and Large Locations Contract Pricing HCP Offer Terms & Conditions

This offer is limited to licensed U.S. healthcare providers who (i) are members of the ASPIRE Galderma Practice Rewards Signature Suite healthcare professional loyalty program or (ii) qualify for the Galderma PRIVI multiple location offer and are associated with a Galderma pricing contract (both (i) and (ii) above are applicable only to healthcare providers who own or operate, or are employed by, a practice with 30 or more locations as determined by Galderma in its sole discretion and exclude healthcare providers in U.S. territories and possessions) (“Qualifying HCPs”). This is a limited quantity offer subject to availability from Galderma. If you have questions about this offer, please call 1-844-5ASPIRE.

Offer 1

Beginning June 24, 2024 and ending December 31, 2024 (or earlier as determined by Galderma in its sole discretion), this offer provides a Qualifying HCP’s practice that makes a qualifying purchase of 44 syringes of Restylane®, Restylane-L®, Restylane® Silk, Restylane® Lyft, Restylane® Refyne, Restylane® Defyne, Restylane® Contour, Restylane® Kysse, and/or Restylane® Eyelight (“Restylane Filler”) and 18 kits (36 vials) of Sculptra® an opportunity to sign a Provider Agreement (and any associated agreements and documents) (the “Agreements”) provided by PatientFi, LLC (“PatientFi”) for access to Galderma PRIVI for twelve (12) months from the date of execution of the Agreements.

Purchases must be made in exact amounts of 44 syringes of Restylane Filler and 18 Sculptra kits to qualify. If a purchase qualifies a Qualifying HCP’s practice for both this offer and another ASPIRE promotional offer, the purchase shall be applied to the other ASPIRE promotional offer in lieu of this offer. Maximum of one (1) qualifying purchase per Qualifying HCP’s practice during the offer duration.

Offer 2

Beginning June 30, 2024 and ending December 31, 2024 (or earlier as determined by Galderma in its sole discretion), this offer provides a Qualifying HCP’s practice that makes a qualifying purchase of 88 syringes of Restylane®, Restylane-L®, Restylane® Silk, Restylane® Lyft, Restylane® Refyne, Restylane® Defyne, Restylane® Contour, Restylane® Kysse, and/or Restylane® Eyelight (“Restylane Filler”) an opportunity to sign a Provider Agreement (and any associated agreements and documents) (the “Agreements”) provided by PatientFi, LLC (“PatientFi”) for access to Galderma PRIVI for twelve (12) months from the date of execution of the Agreements.

Purchases must be made in exact amounts of 88 syringes of Restylane Filler to qualify. If a purchase qualifies a Qualifying HCP’s practice for both this offer and another ASPIRE promotional offer, the purchase shall be applied to the other ASPIRE promotional offer in lieu of this offer. Maximum of one (1) qualifying purchase per Qualifying HCP’s practice during the offer duration.

Additional Terms

In addition, if the Qualifying HCP’s practice enrolls 50 or more new patient Members per quarter in Galderma PRIVI (with quarters defined in relation to the practice’s respective twelve (12) month Galderma PRIVI access and enrollment defined by PatientFi including, without limitation, patient Member execution of any Membership Agreement, authorization(s), and associated documents), the Qualifying HCP’s practice shall also receive 25 $50 Provider Codes for use with their patients in ASPIRE. Maximum of 3 Provider Codes per patient: 1 for a qualifying Dysport® treatment, 1 per syringe for a qualifying Restylane® family treatment, and/or 1 per vial for a qualifying Sculptra® treatment. All Provider Codes shall expire sixty (60) days from the date issued.

Healthcare providers may use Provider Codes only for adult patients who receive treatment with a Galderma aesthetic product (“Galderma Product”) in accordance with the product’s FDA-approved indication and labeling. Member patients must also be members of the ASPIRE Galderma Rewards Consumer Loyalty Program (“ASPIRE”). Galderma employees and their spouses are not eligible to use Provider Codes.

Important Safety Information

Indication: Dysport® (abobotulinumtoxinA) for Injection is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adults ˂65 years of age.

WARNING: DISTANT SPREAD OF TOXIN EFFECT

Postmarketing reports indicate that the effects of Dysport and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses and in approved indications, cases of spread of effect have been reported at doses comparable to or lower than the maximum recommended total dose.

CONTRAINDICATIONS

Hypersensitivity to any botulinum toxin product or excipients
Allergy to cow’s milk protein
Infection at the proposed injection site(s)

WARNINGS AND PRECAUTIONS

The potency Units of Dysport are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of Dysport cannot be compared to or converted into units of any other botulinum toxin products.
Immediate medical attention may be required in cases of respiratory, speech or swallowing difficulties.
Recommended dose and frequency of administration should not be exceeded.
Dry eye may occur with glabellar line treatment, if symptoms persist, consider referring patient to an ophthalmologist.
Concomitant neuromuscular disorder may exacerbate clinical effects of treatment.

ADVERSE REACTIONS

In clinical studies, the most frequently reported adverse events (≥2%) were nasopharyngitis, headache, injection site pain, injection site reaction, upper respiratory tract infection, eyelid edema, eyelid ptosis, sinusitis, nausea, and blood present in urine.

DRUG INTERACTIONS

Concomitant use of Dysport and aminoglycosides or other agents interfering with neuromuscular transmission or muscle relaxants, should be observed closely because effect of Dysport may be potentiated.
Anticholinergic drugs may potentiate systemic anticholinergic effects.
The effect of administering different botulinum neurotoxins during course of treatment with Dysport is unknown.

USE IN SPECIFIC POPULATIONS

Dysport is not recommended for use in children or pregnant women.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see Dysport Full Prescribing Information including Medication Guide at DysportUSA.com

Important Safety Information for the Restylane® Family of Products

The Restylane family of products are indicated for patients over the age of 21, and includes Restylane®, Restylane-L®, Restylane® Lyft with Lidocaine, Restylane® Silk, Restylane® Kysse, Restylane® Refyne, Restylane® Defyne, Restylane® Contour, and Restylane® Eyelight.

APPROVED USES

Restylane^® and Restylane–L^® are for mid-to-deep injection into the facial tissue for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds. Restylane^® and Restylane-L^® are also indicated for injection into the lips.

Restylane^® Lyft with Lidocaine is for deep implantation into the facial tissue for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds and for cheek augmentation and for the correction of age-related midface contour deficiencies. Restylane^® Lyft with Lidocaine is also indicated for injection into the dorsal hand to correct volume loss.

Restylane^® Silk is for lip augmentation and for correction of perioral wrinkles.

Restylane^® Kysse is for lip augmentation and for correction of upper perioral wrinkles.

Restylane^® Refyne is for mid-to-deep injection into the facial tissue for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds.

Restylane^® Defyne is for mid-to-deep injection into the facial tissue for the correction of moderate to severe deep facial wrinkles and folds, such as nasolabial folds. Restylane^® Defyne is also indicated for injection into the mid-to deep dermis (subcutaneous and/or supraperiosteal) for augmentation of the chin region to improve the chin profile in patients with mild to moderate chin retrusion.

Restylane® Contour is for cheek augmentation and for the correction of midface contour deficiencies.

Restylane® Eyelight is for the improvement of infraorbital hollowing.

Do not use if you have severe allergies with a history of severe reactions (anaphylaxis), are allergic to lidocaine or gram-positive bacterial proteins used to make hyaluronic acid, prone to bleeding, or have a bleeding disorder. The safety of use while pregnant or breastfeeding has not been studied. Tell your doctor if you have a history of scarring or pigmentation disorders as these side effects can occur with hyaluronic acid fillers. Tell your doctor if you are planning other cosmetic treatments (i.e., lasers and chemical peels) as there is a possible risk of inflammation at the injection site.

Tell your doctor if you’re taking medications that lower your body’s immune response or affect bleeding, such as aspirin or warfarin, as these medications may increase the risk of bruising or bleeding at the gel injection site. Using these products on gel injection sites with skin sores, pimples, rashes, hives, cysts, or infections should be postponed until healing is complete.

The most common side effects are swelling, redness, pain, bruising, headache, tenderness, lump formation, itching at the injection site, and impaired hand function. Delayed-onset inflammation near the site of dermal filler injections is one of the known adverse events associated with dermal fillers, and cases have been reported to occur at the dermal filler treatment site following viral or bacterial illnesses or infections, vaccinations, or dental procedures. Typically, the reported inflammation was responsive to treatment or resolved on its own. Serious but rare side effects include delayed onset infections, recurrence of herpetic eruptions, and superficial necrosis at the injection site. The risk of unintentional injection into a blood vessel is small but can occur and could result in serious complications, which may be permanent including, vision abnormalities, blindness, stroke, temporary scabs, or permanent scarring of the skin. As with all skin injection procedures, there is a risk of infection.

To report a side effect with any Restylane® product, please call Galderma Laboratories, L.P. at 1-855-425-8722.

To learn more about serious but rare side effects and full Important Safety Information, visit www.RestylaneUSA.com.

Important Safety Information for Sculptra®

Indication: Sculptra® (injectable poly-L-lactic acid (PLLA-SCA)) is indicated for use in people with healthy immune systems for the correction of shallow to deep nasolabial fold contour deficiencies, fine lines and wrinkles in the cheek region, and other facial wrinkles.

Sculptra should not be used by people that are allergic to any ingredient of the product or have a history of keloid formation or hypertrophic scarring. Safety has not been established in patients who are pregnant, lactating, breastfeeding, or under 18 years of age.

Sculptra has unique injection requirements and should only be used by a trained healthcare practitioner. Contour deficiencies should not be overcorrected because they are expected to gradually improve after treatment.

Sculptra should not be injected into the blood vessels as it may cause vascular occlusion, infarction or embolic phenomena. Use at the site of skin sores, cysts, pimples, rashes, hives or infection should be postponed until healing is complete. Sculptra should not be injected into the red area (vermillion) of the lip or in the peri-orbital area.

The most common side effects after initial treatment include injection site swelling, tenderness, redness, pain, bruising, bleeding, itching and lumps. Other side effects may include small lumps under the skin that are sometimes noticeable when pressing on the treated area. Larger lumps, some with delayed onset with or without inflammation or skin discoloration, have also been reported.

Sculptra is available only through a licensed practitioner. Complete Instructions for Use are available at www.SculptraUSA.com/IFU.

Galderma PatientFi ASPIRE Signature Suite and Contract Pricing HCP Offer Terms & Conditions

Galderma PatientFi ASPIRE Signature Suite and Contract Pricing HCP Offer Terms & Conditions

Galderma PatientFi ASPIRE Signature Suite and Large Locations Contract Pricing HCP Offer Terms & Conditions

Welcome!Let's get you to the right page.

Select your specialty below to see how PatientFi works for your type of practice.

Submit a CCPA Privacy Request

Welcome!
Let's get you to the right page.